Immuno- inflammatory markers of bipolar disorder: A review of evidence

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 6, 2012, Pages 2170-2182

  Hamdani, Nora ^a,b,c,d,e   Tamouza, Ryad ^d,e   Leboyer, Marion ^a,b,c,e  

^a FACULTÉ DE MÉDECINE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c INSERM U955   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e FONDATION FONDAMENTAL   (France)

Author keywords

Bipolar disorder; Immunity; Inflammation; Retroviruses; Review; Viruses

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; CELECOXIB; GAMMA INTERFERON; ICOSAPENTAENOIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; REBOXETINE; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ADAPTIVE IMMUNITY; ANTIMALARIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; AUTOIMMUNITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BORNA DISEASE; DEPRESSION; DISEASE ASSOCIATION; GENETIC PREDISPOSITION; HERPES LABIALIS; HUMAN; HYPOMANIA; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOGENETICS; INFLAMMATION; INNATE IMMUNITY; MANIA; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PSYCHOPHARMACOTHERAPY; RETROVIRUS; SEASONAL VARIATION; SINGLE NUCLEOTIDE POLYMORPHISM; SPRING; SYSTEMATIC REVIEW; VIRUS REACTIVATION; WINTER; IMMUNOLOGY; METABOLISM; REVIEW; VIROLOGY;

HUMAN ENDOGENOUS RETROVIRUSES;

AUTOIMMUNITY; BIPOLAR DISORDER; HUMANS; INFLAMMATION;

EID: 84860844973     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e534     Document Type: Article

References (144)

1. DJ Kupfer: The increasing medical burden in bipolar disorder. Jama, 293(20), 2528-30 (2005)) (Pubitemid 40705735)
2. M Leboyer and DJ Kupfer: Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry, 71(12), 1689-95 (2010))
3. RH Yolken and EF Torrey: Are some cases of psychosis caused by microbial agents? Mol Psychiatry, 13, 470-479 (2008)) (Pubitemid 351556038)
4. BI Goldstein, DE Kemp, JK Soczynska and RS McIntyre: Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry, 70(8), 1078-90 (2009))
5. C M Eklund: Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem, 48, 111-36 (2009))
6. I Kushner, D Rzewnicki and D Samols: What does minor elevation of C-reactive protein signify? Am J Med, 119(2), 166 e17-28 (2006))
7. MB Howren, DM Lamkin and J Suls: Associations of depression with C-reactive protein, IL-1, and IL-6: a metaanalysis. Psychosom Med, 71(2), 171-86 (2009))
8. JA Pasco, GC Nicholson, LJ Williams, FN Jacka, MJ Henry, MA Kotowicz, HG Schneider, B E Leonard and M Berk: Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry, 197, 372-77
9. AA Wadee, RH Kuschke, LA Wood, M Berk, L Ichim and M Maes: Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol, 17(4), 175-9 (2002)) (Pubitemid 34678878)
10. TL Huang and FC Lin: High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry, 31(2), 370-2 (2007))
11. F Dickerson, C Stallings, A Origoni, J Boronow and R Yolken: Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry, 31(4), 952-5 (2007)) (Pubitemid 46660310)
12. D De Berardis, CM Conti, D Campanella, A Carano, M Scali, A Valchera, N Serroni, AM Pizzorno, A D'Albenzio, M Fulcheri, F Gambi, R La Rovere, C Cotellessa, R M Salerno and F M Ferro: Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol, 21(2), 319-24 (2008)) (Pubitemid 351988393)
13. AB Cunha, AC Andreazza, FA Gomes, BN Frey, LE da Silveira, CA Goncalves and F Kapczinski: Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci, 258(5), 300-4 (2008))
14. Z Kronfol and DG Remick: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry, 157(5), 683-94 (2000)) (Pubitemid 30249643)
15. R Sapolsky, C Rivier, G Yamamoto, P Plotsky and W Vale: Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science, 238(4826), 522-4 (1987)) (Pubitemid 17147036)
16. EW Bernton, JE Beach, JW Holaday, RC Smallridge and HG Fein: Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science, 238(4826), 519-21 (1987)) (Pubitemid 17147035)
17. HO Besedovsky, A del Rey, I Klusman, H Furukawa, G Monge Arditi and A Kabiersch: Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J Steroid Biochem Mol Biol, 40(4-6), 613-8 (1991))
18. RJ Schloesser, G Chen and HK Manji: Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder. Int Rev Neurobiol, 77, 143-78 (2007))
19. YK Kim, HG Jung, AM Myint, H Kim and SH Park: Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord, 104(1-3), 91-5 (2007)) (Pubitemid 350064526)
20. A Ortiz-Dominguez, ME Hernandez, C Berlanga, D Gutierrez-Mora, J Moreno, G Heinze and L Pavon: Immune variations in bipolar disorder: phasic differences. Bipolar Disord, 9(6), 596-602 (2007)) (Pubitemid 47365627)
21. SM O'Brien, P Scully, L V Scott and TG Dinan: Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord, 90(2-3), 263-7 (2006)) (Pubitemid 43183536)
22. MH Rapaport, L Guylai and P Whybrow: Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res, 33(4), 335-40 (1999)) (Pubitemid 29267636)
23. SY Tsai, KP Chen, YY Yang, CC Chen, JC Lee, VK Singh and SJ Leu: Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry, 45(8), 989-94 (1999)) (Pubitemid 29219619)
24. E Brietzke, M Kauer-Sant'Anna, AL Teixeira and F Kapczinski: Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun, 23(8), 1079-82 (2009))
25. EM Knijff, MN Breunis, RW Kupka, HJ de Wit, C Ruwhof, GW Akkerhuis, WA Nolen and HA Drexhage: An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord, 9(7), 743-53 (2007)) (Pubitemid 350042410)
26. V Mollace, C Muscoli, E Masini, S Cuzzocrea and D Salvemini: Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev, 57(2), 217-52 (2005)) (Pubitemid 41043885)
27. AC Andreazza, M Kauer-Sant'anna, BN Frey, DJ Bond, F Kapczinski, LT Young and LN Yatham: Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord, 111(2-3), 135-44 (2008))
28. JS Rao, G J Harry, SI Rapoport and HW Kim: Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry, 15(4), 384-922
29. F Kapczinski, VV Dias, M Kauer-Sant'Anna, E Brietzke, GH Vazquez, E Vieta and M Berk: The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry, 33(8), 1366-71 (2009))
30. M Berk, P Conus, N Lucas, K Hallam, GS Malhi, S Dodd, LN Yatham, A Yung and P McGorry: Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord, 9(7), 671-8 (2007)) (Pubitemid 350042401)
31. M Berk, K Hallam, N Lucas, M Hasty, CA McNeil, P Conus, L Kader and PD McGorry: Early intervention in bipolar disorder: opportunities and pitfalls. Med J Aust, 187(7 Suppl), S11-4 (2007))
32. AC Andreazza, F Kapczinski, M Kauer-Sant'Anna, JC Walz, DJ Bond, CA Goncalves, LT Young and LN Yatham: 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci, 34(4), 263-71 (2009))
33. M Kauer-Sant'Anna, F Kapczinski, AC Andreazza, DJ Bond, RW Lam, LT Young and LN Yatham: Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol, 12(4), 447-58 (2009))
34. W W Eaton, M G Pedersen, P R Nielsen and P B Mortensen: Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord, 12(6), 638-46 (2010))
35. R Vonk, AC van der Schot, RS Kahn, WA Nolen and HA Drexhage: Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry, 62(2), 135-40 (2007)) (Pubitemid 46963249)
36. RS McIntyre, JZ Konarski, VL Misener and SH Kennedy: Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry, 17(2), 83-93 (2005)) (Pubitemid 40967131)
37. F Cassidy, E Ahearn and B J Carroll: Elevated frequency of diabetes mellitus in hospitalized manicdepressive patients. Am J Psychiatry, 156(9), 1417-20 (1999)) (Pubitemid 29416540)
38. RW Kupka and EJ Regeer: [Bipolar mood disorders]. Ned Tijdschr Geneeskd, 151(41), 2256-60 (2007))
39. EG Severance, FB Dickerson, M Halling, B Krivogorsky, L Haile, S Yang, C R Stallings, AE Origoni, I Bossis, J Xiao, D Dupont, W Haasnoot and RH Yolken: Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res, 118(1-3), 240-7
40. G Pawelec, Y Barnett, R Forsey, D Frasca, A Globerson, J McLeod, C Caruso, C Franceschi, T Fulop, S Gupta, E Mariani, E Mocchegiani and R Solana: T cells and aging, January 2002 update. Front Biosci, 7, d1056-183 (2002))
41. AP Cerri, B Arosio, C Viazzoli, R Confalonieri, C Vergani and G Annoni: The -308 (G/A) single nucleotide polymorphism in the TNF-alpha gene and the risk of major depression in the elderly. Int J Geriatr Psychiatry, 25(3), 219-23
42. M Clerici, B Arosio, E Mundo, E Cattaneo, S Pozzoli, B Dell'osso, C Vergani, D Trabattoni and AC Altamura: Cytokine polymorphisms in the pathophysiology of mood disorders. CNS Spectr, 14(8), 419-25 (2009))
43. PM Czerski, F Rybakowski, P Kapelski, JK Rybakowski, M Dmitrzak-Weglarz, A Leszczynska-Rodziewicz, A Slopien, M Skibinska, M Kaczmarkiewicz-Fass and J Hauser: Association of tumor necrosis factor - 308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology, 57(1-2), 88-94 (2008)) (Pubitemid 351859339)
44. CA Dinarello: The IL-1 family and inflammatory diseases. Clin Exp Rheumatol, 20(5 Suppl 27), S1-13 (2002))
45. JP Hwang, SJ Tsai, CJ Hong, CH Yang, CD Hsu and YJ Liou: Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. Neuromolecular Med, 11(4), 322-7 (2009))
46. S Papiol, V Molina, M Desco, A Rosa, S Reig, J Sanz, T Palomo and L Fananas: Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13) Genes Brain Behav, 7(7), 796-801 (2008))
47. RC Padmos, MH Hillegers, EM Knijff, RVonk, A Bouvy, FJ Staal, D de Ridder, RW Kupka, WA Nolen and HA Drexhage: A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry, 65(4), 395-407 (2008)) (Pubitemid 351519889)
48. R H Yolken and E F Torrey: Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev, 8(1), 131-45 (1995))
49. E F Torrey, J Miller, R Rawlings and R H Yolken: Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res, 28(1), 1-38 (1997)) (Pubitemid 27522788)
50. EF Torrey, RR Rawlings, JM Ennis, DD Merrill and DS Flores: Birth seasonality in bipolar disorder, schizophrenia, schizoaffective disorder and stillbirths. Schizophr Res, 21(3), 141-9 (1996)) (Pubitemid 26298406)
51. PB Moore, S M El-Badri, D Cousins, D J Shepherd, AH Young, VL McAllister and IN Ferrier: White matter lesions and season of birth of patients with bipolar affective disorder. Am J Psychiatry, 158(9), 1521-4 (2001))
52. J Chotai and M Asberg: Variations in CSF monoamine metabolites according to the season of birth. Neuropsychobiology, 39(2), 57-62 (1999)) (Pubitemid 29118951)
53. J Chotai and R Adolfsson: Converging evidence suggests that monoamine neurotransmitter turnover in human adults is associated with their season of birth. Eur Arch Psychiatry Clin Neurosci, 252(3), 130-4 (2002)) (Pubitemid 36062419)
54. J Chotai, A Serretti, E Lattuada, C Lorenzi and R Lilli: Gene-environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. Psychiatry Res, 119(1-2), 99-111 (2003)) (Pubitemid 36829422)
55. F Dickerson, B Kirkpatrick, J Boronow, C Stallings, A Origoni and R Yolken: Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull, 32(2), 396-400 (2006))
56. DW Niebuhr, AM Millikan, DN Cowan, R Yolken, Y Li and NS Weber: Selected infectious agents and risk of schizophrenia among U.S. military personnel. Am J Psychiatry, 165(1), 99-106 (2008)) (Pubitemid 351704558)
57. H Terayama, Y Nishino, M Kishi, K Ikuta, M Itoh and K Iwahashi: Detection of anti-Borna Disease Virus (BDV) antibodies from patients with schizophrenia and mood disorders in Japan. Psychiatry Res, 120(2), 201-6 (2003)) (Pubitemid 37176994)
58. R Ferszt, E Severus, L Bode, M Brehm, KP Kuhl, H Berzewski and H Ludwig: Activated Borna disease virus in affective disorders. Pharmacopsychiatry, 32(3), 93-8 (1999)) (Pubitemid 29364442)
59. FB Dickerson, J J Boronow, C Stallings, A E Origoni, S Cole, B Krivogorsky and RH Yolken: Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry, 55(6), 588-93 (2004)) (Pubitemid 38315032)
60. DJ Griffiths: Endogenous retroviruses in the human genome sequence. Genome Biol, 2(6), reviews1017 (2001))
61. A Venter: New protein blocks HIV. Trends Microbiol, 9(3), 110 (2001))
62. H Perron, L Mekaoui, C Bernard, F Veas, I Stefas and M Leboyer: Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol Psychiatry, 64(12), 1019-23 (2008))
63. JL Blond, F Beseme, L Duret, O Bouton, F Bedin, H Perron, B Mandrand and F Mallet: Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J Virol, 73(2), 1175-85 (1999)) (Pubitemid 29036769)
64. H S Kim and WH Lee: Human endogenous retrovirus HERV-W family: chromosomal localization, identification, and phylogeny. AIDS Res Hum Retroviruses, 17(7), 643-8 (2001))
65. F Komurian-Pradel, G Paranhos-Baccala, F Bedin, A Ounanian-Paraz, M Sodoyer, C Ott, A Rajoharison, E Garcia, F Mallet, B Mandrand and H Perron: Molecular cloning and characterization of MSRV-related sequences associated with retrovirus-like particles. Virology, 260(1), 1-9 (1999)) (Pubitemid 29391727)
66. H Perron, C Geny, O Genoulaz, J Pellat, J Perret and JM Seigneurin: Antibody to reverse transcriptase of human retroviruses in multiple sclerosis. Acta Neurol Scand, 84(6), 507-13 (1991))
67. H Perron, JA Garson, F Bedin, F Beseme, G Paranhos-Baccala, F Komurian-Pradel, F Mallet, PW Tuke, C Voisset, J L Blond, B Lalande, J M Seigneurin and B Mandrand: Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A, 94(14), 7583-8 (1997))
68. H Perron, J P Perin, F Rieger and PM Alliel: Particleassociated retroviral RNA and tandem RGH/HERV-W copies on human chromosome 7q: possible components of a 'chain-reaction' triggered by infectious agents in multiple sclerosis? J Neurovirol, 6 Suppl 2, S67-75 (2000)) (Pubitemid 30348915)
69. P Deb-Rinker, TA Klempan, RL O'Reilly, EF Torrey and SM Singh: Molecular characterization of a MSRV-like sequence identified by RDA from monozygotic twin pairs discordant for schizophrenia. Genomics, 61(2), 133-44 (1999)) (Pubitemid 29514137)
70. H Karlsson, S Bachmann, J Schroder, J McArthur, EF Torrey and RH Yolken: Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci U S A, 98(8), 4634-9 (2001))
71. H Karlsson, J Schroder, S Bachmann, C Bottmer and R H Yolken: HERV-W-related RNA detected in plasma from individuals with recent-onset schizophrenia or schizoaffective disorder. Mol Psychiatry, 9(1), 12-3 (2004))
72. W J Huang, Z C Liu, W Wei, G H Wang, J G Wu and F Zhu: Human endogenous retroviral pol RNA and protein detected and identified in the blood of individuals with schizophrenia. Schizophr Res, 83(2-3), 193-9 (2006))
73. Y Yao, J Schroder, C Nellaker, C Bottmer, S Bachmann, RH Yolken and H Karlsson: Elevated levels of human endogenous retrovirus-W transcripts in blood cells from patients with first episode schizophrenia. Genes Brain Behav, 7(1), 103-12 (2008))
74. R H Yolken, H Karlsson, F Yee, N L Johnston-Wilson and E F Torrey: Endogenous retroviruses and schizophrenia. Brain Res Brain Res Rev, 31(2-3), 193-9 (2000)) (Pubitemid 30136176)
75. O Frank, M Giehl, C Zheng, R Hehlmann, C Leib-Mosch and W Seifarth: Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorder. J Virol, 79(17), 10 890-901 (2005)) (Pubitemid 41170631)
76. S Weis, I C Llenos, S Sabunciyan, J R Dulay, L Isler, R Yolken and H Perron: Reduced expression of human endogenous retrovirus (HERV)-W GAG protein in the cingulate gyrus and hippocampus in schizophrenia, bipolar disorder, and depression. J Neural Transm, 114(5), 645-55 (2007)) (Pubitemid 46664044)
77. C Nellaker, Y Yao, L Jones-Brando, F Mallet, R H Yolken and H Karlsson: Transactivation of elements in the human endogenous retrovirus W family by viral infection. Retrovirology, 3, 44 (2006))
78. H Perron, M Suh, B Lalande, B Gratacap, A Laurent, P Stoebner and J M Seigneurin: Herpes simplex virus ICP0 and ICP4 immediate early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell line from a patient with multiple sclerosis. J Gen Virol, 74 ( Pt 1), 65-72 (1993)) (Pubitemid 23053767)
79. T J Crow: Influenza and schizophrenia. Br J Psychiatry, 171, 91 (1997))
80. T Ebert and M Kotler: Prenatal exposure to influenza and the risk of subsequent development of schizophrenia. Isr Med Assoc J, 7(1), 35-8 (2005)) (Pubitemid 40123554)
81. F Limosin, F Rouillon, C Payan, J M Cohen and N Strub: Prenatal exposure to influenza as a risk factor for adult schizophrenia. Acta Psychiatr Scand, 107(5), 331-5 (2003)) (Pubitemid 36606149)
82. T J Crow: A re-evaluation of the viral hypothesis: is psychosis the result of retroviral integration at a site close to the cerebral dominance gene? Br J Psychiatry, 145, 243-53 (1984)) (Pubitemid 14066473)
83. M Lafon, E Jouvin-Marche, PN Marche and H Perron: Human viral superantigens: to be or not to be transactivated? Trends Immunol, 23(5), 238-9; author reply 239 (2002)) (Pubitemid 34499559)
84. K Morimoto, T Murasugi and T Oda: Acute neuroinflammation exacerbates excitotoxicity in rat hippocampus in vivo. Exp Neurol, 177(1), 95-104 (2002)) (Pubitemid 35356825)
85. J M Antony, G van Marle, W Opii, D A Butterfield, F Mallet, VW Yong, J L Wallace, RM Deacon, K Warren and C Power: Human endogenous retrovirus glycoproteinmediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci, 7(10), 1088-95 (2004)) (Pubitemid 41184449)
86. J M Antony, Y Zhu, M Izad, K G Warren, M Vodjgani, F Mallet and C Power: Comparative expression of human endogenous retrovirus-W genes in multiple sclerosis. AIDS Res Hum Retroviruses, 23(10), 1251-6 (2007))
87. J Piret, N Gagne, S Perron, A Desormeaux, M J Tremblay, P Gourde, R F Omar and A M Bergeron: Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and herpes simplex virus type 2. Sex Transm Dis, 28(8), 484-91 (2001)) (Pubitemid 32730298)
88. A Rolland, E Jouvin-Marche, C Viret, M Faure, H Perron and P N Marche: The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol, 176(12), 7636-44 (2006)) (Pubitemid 43849064)
89. M Sommerlund, G Pallesen, A Moller-Larsen, HJ Hansen and S Haahr: Retrovirus-like particles in an Epstein-Barr virus-producing cell line derived from a patient with chronic progressive myelopathy. Acta Neurol Scand, 87(2), 71-6 (1993)) (Pubitemid 23051530)
90. N Sutkowski, B Conrad, D A Thorley-Lawson and BT Huber: Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity, 15(4), 579-89 (2001)) (Pubitemid 33016443)
91. L Shenkman, W Borkowsky and B Shopsin: Lithium as an immunologic adjuvant. Med Hypotheses, 6(1), 1-6 (1980)) (Pubitemid 10080776)
92. J Lieb: Immunopotentiation and inhibition of herpes virus activation during therapy with lithium carbonate. Med Hypotheses, 7(7), 885-90 (1981)) (Pubitemid 11012070)
93. J D Amsterdam, G Maislin and J Rybakowski: A possible antiviral action of lithium carbonate in herpes simplex virus infections. Biol Psychiatry, 27(4), 447-53 (1990)) (Pubitemid 20083773)
94. J Lieb: Lithium and antidepressants: stimulating immune function and preventing and reversing infection. Med Hypotheses, 69(1), 8-11 (2007)) (Pubitemid 46686964)
95. JD Amsterdam, G Maislin, L Potter and R Giuntoli: Reduced rate of recurrent genital herpes infections with lithium carbonate. Psychopharmacol Bull, 26(3), 343-7 (1990)) (Pubitemid 20386907)
96. J Lieb: Lithium and antidepressants: inhibiting eicosanoids, stimulating immunity, and defeating microorganisms. Med Hypotheses, 59(4), 429-32 (2002))
97. JR Calabrese, D J Rapport, MD Shelton, M Kujawa and S E Kimmel: Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology, 38(3), 185-91 (1998)) (Pubitemid 28479455)
98. LJones-Brando, E F Torrey and R Yolken: Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res, 62(3), 237-44 (2003)) (Pubitemid 36775365)
99. S Vale, M A Espejel and J C Dominguez: Amantadine in depression. Lancet, 2(7721), 437 (1971))
100. L Bode, DE Dietrich, R Stoyloff, H M Emrich and H Ludwig: Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet, 349(9046), 178-9 (1997)) (Pubitemid 27039203)
101. D E Dietrich, L Bode, C W Spannhuth, T Lau, T J Huber, B Brodhun, H Ludwig and H M Emrich: Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord, 2(1), 65-70 (2000))
102. L Bode, R Ferszt and G Czech: Borna disease virus infection and affective disorders in man. Arch Virol, Suppl, 7, 159-67 (1993))
103. L Bode, R Durrwald, F A Rantam, R Ferszt and H Ludwig: First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry, 1(3), 200-12 (1996)) (Pubitemid 126441293)
104. TJ Huber, DE Dietrich and HM Emrich: Possible use of amantadine in depression. Pharmacopsychiatry, 32(2), 47-55 (1999)) (Pubitemid 29197549)
105. M Maes, J Calabrese, K Jayathilake and HY Meltzer: Effects of subchronic treatment with valproate on L-5- HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res, 71(2), 67-76 (1997)) (Pubitemid 27281611)
106. M Maes, J Delange, R Ranjan, H Y Meltzer, R Desnyder, W Cooremans and S Scharpe: Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res, 66(1), 1-11 (1997)) (Pubitemid 27111375)
107. MH Rapaport: Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord, 32(3), 149-56 (1994))
108. A Sluzewska, M Sobieska and J K Rybakowski: Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology, 35(3), 123-7 (1997)) (Pubitemid 27196534)
109. M Bubak-Satora, A Skowron-Cendrzak and M Kubera: The effect of lithium chloride treatment on cellmediated immunity in mice. Folia Biol (Krakow), 39(1-4), 21-4 (1991))
110. I Krause, J Cohen, M Blank, R Bakimer, A Cartman, A Hohmann, G Valesini, RA Asherson, MA Khamashta, GR Hughes et al.: Distribution of two common idiotypes of anticardiolipin antibodies in sera of patients with primary antiphospholipid syndrome, systemic lupus erythematosus and monoclonal gammopathies. Lupus, 1(2), 91-6 (1992))
111. E J Kucharz, S J Sierakowski and J S Goodwin: Lithium in vitro enhances interleukin-2 production by T cells from patients with systemic lupus erythematosus. Immunopharmacol Immunotoxicol, 15(5), 515-23 (1993)) (Pubitemid 23353422)
112. P Stolk, P C Souverein, I Wilting, H G Leufkens, D F Klein, S I Rapoport and E R Heerdink: Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids, 82(1), 9-14
113. E Collantes-Estevez and C Fernandez-Perez: Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin, 19(5), 402-10 (2003)) (Pubitemid 36994443)
114. N Muller, M Riedel and M J Schwarz: Psychotropic effects of COX-2 inhibitors - a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry, 37(6), 266-9 (2004)) (Pubitemid 39587053)
115. N Muller, M J Schwarz, S Dehning, A Douhe, A Cerovecki, B Goldstein-Muller, I Spellmann, G Hetzel, K Maino, N Kleindienst, H J Moller, V Arolt and M Riedel: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry, 11(7), 680-4 (2006)) (Pubitemid 43989814)
116. P Casolini, A Catalani, A R Zuena and L. Angelucci: Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res, 68(3), 337-43 (2002)) (Pubitemid 34462539)
117. N Muller, M Strassnig, M J Schwarz, M Ulmschneider and M Riedel: COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opin Investig Drugs, 13(8), 1033-44 (2004)) (Pubitemid 39117689)
118. S Akhondzadeh, M Tabatabaee, H Amini, S A Ahmadi Abhari, S H Abbasi and B Behnam: Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res, 90(1-3), 179-85 (2007)) (Pubitemid 46177578)
119. N Muller, D Krause, S Dehning, R Musil, R Schennach-Wolff, M Obermeier, HJ Moller, V Klauss, MJ Schwarz and M Riedel: Celecoxib treatment in an early stage of schizophrenia: results of a randomized, doubleblind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res, 121(1-3), 118-24
120. S Frangou, M Lewis and P McCrone: Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry, 188, 46-50 (2006)) (Pubitemid 43021926)
121. MJ Finnen and CR Lovell: Purification and characterisation of phospholipase A2 from human epidermis. Biochem Soc Trans, 19(2), 91S (1991))
122. MC Chang and C R Jones: Chronic lithium treatment decreases brain phospholipase A2 activity. Neurochem Res, 23(6), 887-92 (1998)) (Pubitemid 28178162)
123. HF Seung Kim, E J Weeber, J D Sweatt, A L Stoll and L B Marangell: Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry, 6(2), 246-8 (2001)) (Pubitemid 32187880)
124. I Upton: Ethyl-eicosapentaenoic acid in bipolar depression. Br J Psychiatry, 189, 191 (2006))
125. Z Kronfol, L LeMay, M Nair, M Kluger: Electroconvulsive therapy increases plasma levels of interleukin-6. Ann NY Acad Sci, 594, 463-465 (1990)) (Pubitemid 20298267)
126. RC Padmos. Inflammatory monocytes in bipolar disorder and related endocrine autoimmune diseases. Thesis, Germany. (2009))
127. F Boufidou, C Nikolaou, B Alevizos, IA Liappas, GN Christodoulou. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord, 82(2), 309-13 (2004)) (Pubitemid 39370835)
128. Report of the Committee of the Clinical Society of London to investigate the subject of myxoedema. Trans Clinical Society of London. 1888. 21(suppl) 1-215
129. TW Heinrich, G Grahm: Hypothyroidism Presenting as Psychosis: Myxedema Madness Revisited. Prim Care Companion. J Clin Psychiatry, 5(6):260-266 (2003))
130. E Thorsby, BA Lie: HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transpl Immunol, 14(3-4), 175-82 (2005)) (Pubitemid 40848523)
131. J Biederman, M Keller, P Lavori, J Harmatz, D Knee, D Dubey, E. Yunis: HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry, 22(2), 221-4 (1987)) (Pubitemid 17222136)
132. TT Sorokina, RA Evsegneev, VI Levin, GV Semenov: Features of the distribution of HLA-antigens among patients with endogenous psychose]. Zh Nevropatol Psikhiatr Im S S Korsakova, 87(6), 885-8 (1987))
133. ME Ozcan, R Taskin, R Banoglu, M Babacan, E Tuncer: HLA antigens in schizophrenia and mood disorders. Biol Psychiatry, 15;39(10), 891-5 1996 (Pubitemid 26163535)
134. T Ventura, A Lobo, JC Marco: HLA antigens in bipolar affective patients. Actas Luso Esp Neurol Psiquiatr Cienc Afines, 18(5), 339-43 (1990))
135. A Uçok, U Akar, A Polat, O Yazici: Human leukocyte antigen alleles in patients with bipolardisorder in Turkey. Eur Psychiatry, 20(1), 83 (2005)) (Pubitemid 40092401)
136. VP Bozikas, MC Anagnostouli, P Petrikis, C Sitzoglou, C Phokas, C Tsakanikas, A Karavatos: Familial bipolar disorder and multiple sclerosis: a three-generation HLA family study. Prog Neuropsychopharmacol Biol Psychiatry, 27(5), 835-9 (2003)) (Pubitemid 36966766)
137. Z Kaminsky, M Tochigi, P Jia, M Pal, J Mill, A Kwan, I Ioshikhes, JB Vincent, JL Kennedy, J Strauss, S Pai, SC Wang, A Petronis: A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Mol Psychiatry, (2011))
138. MN Breunis, RW Kupka, WA Nolen, T Suppes, KD Denicoff, GS Leverich, RM Post, HA Drexhage: High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry, 53(2), 157-65 (2003). (Pubitemid 36126479)
139. YK Kim, HG Jung, AM Myint, H Kim, SH Park: Imbalance between pro-inflammatory and antiinflammatory cytokines in bipolar disorder. J Affect Disord, 104(1-3), 91-5 (2007)) (Pubitemid 350064526)
140. YK Kim, AM Myint, BH Lee, CS Han, SW Lee, BE Leonard, HW Steinbusch: T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res, 129(3), 267-72 (2004)) (Pubitemid 40127539)
141. YK Kim, Suh IB, H Kim, CS Han, CS Lim, SH Choi, J Licinio: The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry, 7(10), 1107-14 (2002)) (Pubitemid 36044270)
142. HC Liu, YY Yang, YM Chou, KP Chen, WW Shen, SJ Leu. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol, 150(1-2), 116-22 (2004)) (Pubitemid 38481654)
143. S Hope, I Melle, P Aukrust, NE Steen, AB Birkenaes, S Lorentzen, I Agartz, T Ueland, OA Andreassen. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord, 11(7), 726-34 (2009))
144. S Guloksuz, EA Cetin, T Cetin, G Deniz, ET Oral, DJ Nutt. Cytokine levels in euthymic bipolar patients. J Affect Disord 126(3), 458-62 (2010))